New hope for rare eye cancer: drug targets spreading tumors
NCT ID NCT01587352
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called vorinostat in 40 people with uveal melanoma that has spread to other parts of the body. The drug works by blocking enzymes that help cancer cells grow. The main goal is to see if the drug can shrink tumors and help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032, United States
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States